Submit tirzepatide for regulatory approval in additional markets
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Oct 2021
- Due
- 31 Dec 2021
- Delivered
- Q4 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Several additional submissions are planned around the world before the end of 2021.”
What we found
Evidence strength A What the grades mean
Eli Lilly confirmed in its 2022 filings that it submitted tirzepatide for regulatory approval in Europe and Japan during 2021, fulfilling the commitment to submit in additional markets before year-end.
-
A ELI Lilly & Co 10-Q filed 2022-08-04
“Tirzepatide (Mounjaro®)Type 2 diabetesApprovedApproved in the U.S. in the second quarter of 2022. Submitted in Europe and Japan in 2021.” ✓ confirmed on the page
Market reaction: the shares moved -3.3% against the S&P 500 over the three sessions around the disclosure (3 Aug 2022 to 8 Aug 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- tirzepatide regulatory submissions
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LLY-004260 · Corrections policy